Jamie S Lin, MD, FASN
Department of Emergency Medicine, Division of Internal Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Section of Nephrology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2010 | University of Nebraska Medical Center College of Medicine, Omaha, NE, USA, MD, Medicine |
| 2005 | University of Pennsylvania, Philadelphia, PA, USA, BA, Biological Basis of Behavior |
Postgraduate Training
| 2017-2019 | Clinical Fellowship, Onco-Nephrology, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2015-2017 | Research Fellowship, Nephrology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA |
| 2013-2015 | Clinical Fellowship, Nephrology, Hospital of the University of Pennsylvania, Philadelphia, PA |
| 2010-2013 | Clinical Residency, Internal Medicine, Baylor College of Medicine, Houston, TX |
Board Certifications
| 2015 | American Board of Internal Medicine, Nephrology |
| 2013 | American Board of Internal Medicine |
Experience & Service
Academic Appointments
Instructor, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - 2020
Other Appointments/Responsibilities
Co-Director IOTOX Nephritis, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - Present
Attending Physician, Penn Presbyterian Hospital, Philadelphia, PA, 2015 - 2017
Attending Physician, Hospital of University of Pennsylvania, Philadelphia, PA, 2015 - 2017
Institutional Committee Activities
Core Development Team Leader, Guidelines for Immune Nephritis, 2022 - Present
Member, Division of Internal Medicine Research Committee, 2021 - Present
Member, Division of Internal Medicine Research Education Subcommittee, 2021 - Present
Research Leader, The University of Texas MD Anderson IOTOX Committee, 2020 - Present
Member, The University of Texas MD Anderson IOTOX Working Group, 2019 - Present
Project Leader, Department of Quality Improvement: DARRT (Dose Adjustment for Renal Replacement Therapy) Task Force, 2018 - Present
Honors & Awards
| 2022 | NCI Loan Repayment Program Award, National Institute of Health |
| 2021 | Best Oral Presentation, Basic Research Forum for Emerging Kidney Scientists, American Society of Nephrology and American Physiological society |
| 2020 | Fellow of ASN, American Society of Nephrology |
| 2019 | DARRT (Dose Adjustment Renal Replacement Therapy) Project, Commission of Cancer Award, The University of Texas MD Anderson Cancer Center |
| 2017 - 2019 | Sharon Anderson Research Fellow, American Society of Nephrology |
| 2016 | Karen L. Campbell American Society of Nephrology Travel Award, American Society of Nephrology |
| 2016 | First place, National Young Investigator’s Forum, National Kidney Foundation |
| 2016 | Third place, Mid-Atlantic Regional Young Investigator Forum, Johns Hopkins University School of Medicine |
| 2014 | Origins of Renal Physiology Mount Desert Island Biologic Laboratory Scholarship, Mount Desert Island Biologic Laboratory |
| 2011 | Kidney STARS Travel Award, American Society of Nephrology |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Shivaraj K, Tchakarov A, Dong Y, Lin JS*. Tofacitinib for the treatment of refractory immune checkpoint inhibitor-associated immune nephritis. Clin Kidney J 17(5):sfae127, 2024. e-Pub 2024. PMID: 38803394.
- Bohat R, Liang X, Chen Y, Xu C, Zheng N, Guerrero A, Hou J, Jaffery R, Egan NA, Li Y, Tang Y, Unsal E, Robles A, Chen S, Major AM, Elldakli H, Chung SH, Liang H, Hicks MJ, Du Y, Lin JS, Chen X, Mohan C, Peng W. Faslpr gene dosage tunes the extent of lymphoproliferation and T cell differentiation in lupus. Clin Immunol 258:109874, 2024. e-Pub 2023. PMID: 38113962.
- Fayle SE, Palaskas NL, Siddiqui BA, McQuade JL, Lin JS, Subudhi SK, Patel AB, Jenq RR, Shah AY, Spelman AR, Sun M, Marble BH, Wang Y. Development of a Strategic Initiative at MD Anderson Cancer Center to Improve Outcomes in Immune-Related Adverse Events. J Natl Compr Canc Netw 22(5), 2024. e-Pub 2024. PMID: 38190801.
- Turcotte AE, Glass WF, Lin JS*, Burger JA*. Membranous nephropathy in chronic lymphocytic leukemia responsive to ibrutinib: A case report. Leuk Res Rep 20:100377, 2023. e-Pub 2023. PMID: 37457553.
- Singh S, Long JP, Tchakarov A, Dong Y, Yee C, Lin JS*. Tertiary lymphoid structure signatures are associated with immune checkpoint inhibitor related acute interstitial nephritis. JCI Insight, 2022. e-Pub 2022. PMID: 36472921.
- Ratanasrimetha P, Reddy VD, Kala J, Tchakarov A, Glass WF, Msaouel P, Lin JS*. Case Report: Successful treatment of late-onset immune checkpoint inhibitor-associated membranous nephropathy in a patient with advanced renal cell carcinoma. Front Immunol 13:898811, 2022. e-Pub 2022. PMID: 35967405.
- Singh S, Clemente LC, Parra ER, Tchakarov A, Yang C, Li Y, Long JP, Yee C, Lin JS*. Urinary T cells are detected in patients with immune checkpoint inhibitor-associated immune nephritis that are clonotypically identical to kidney T cell infiltrates. Oncoimmunology 11(1):2124678, 2022. e-Pub 2022. PMID: 36185804.
- Lin JS, Mamlouk O, Selamet U, Tchakarov A, Glass WF, Sheth RA, Layman RM, Dadu R, Abdelwahab N, Abdelrahim M, Diab A, Yee C, Abudayyeh A. Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis. Oncoimmunology 10(1), 2021. PMID: 33643693.
- Lin JS, Wang DY, Mamlouk O, Glass WF, Abdelrahim M, Yee C, Abudayyeh A. Immune Checkpoint Inhibitor Associated Reactivation of Primary Membranous Nephropathy Responsive to Rituximab. J Immunother Cancer 8(2), 2020. e-Pub 2020. PMID: 33020246.
- Mamlouk O, Lin JS, Abdelrahim M, Tchakarov A, Glass WF, Selamet U, Buni M, Abdelwahab N, Abudayyeh A. Checkpoint inhibitor–related renal vasculitis and use of rituximab. Journal of Immunotherapy Cancer 8(2), 2020. e-Pub 2020. PMID: 32718987.
- Galvan DL, Long J, Green N, Chang BH, Lin JS, Schumacker P, Truong LD, Overbeek P, Danesh FR. Drp1S600 phosphorylation regulates mitochondrial fission and progression of nephropathy in diabetic mice. J Clin Invest 130(7):2807-2823, 2019. e-Pub 2019. PMID: 31063459.
- Mamlouk O, Selamet U, Machado S, Abdelrahim M, Glass WF, Tchakarov A, Gaber L, Lahoti A, Workeneh B, Chen S, Lin J, Abdel-Wahab N, Tayar J, Lu H, Suarez-Almazor M, Tannir N, Yee C, Diab A, Abudayyeh A. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J Immunother Cancer 7(1):2, 2019. e-Pub 2019. PMID: 30612580.
- Mamlouk O, Lin JS, Glass WF, Amaria RN, Lahoti A, Workeneh BT,. Acute Renal failure secondary to multifocal tubulointerstitial and intraglomerular metastatic malignant melanoma. Journal of Onco-Nephrology 2(1):24-30, 2018.
- Ingersoll MA, Chou YW, Lin JS, Yuan TC, Miller DR, Xie Y, Tu Y, Oberley-Deegan RE, Batra SK, Lin MF. p66Shc regulates migration of castration-resistant prostate cancer cells. Cell Signal 46:1-14, 2018. e-Pub 2018. PMID: 29462661.
- Lin FC, Lin JS, Kim S, Walker JR. A rare diaphragmatic ureteral herniation case report: endoscopic and open reconstructive management. BMC Urol 17(1):26, 2017. e-Pub 2017. PMID: 28381270.
- Lin JS, Jeon JS, Fan Q, Wong HN, Palmer MB, Holzman LB. ARF6 mediates nephrin tyrosine phosphorylation-induced podocyte cellular dynamics. PLoS One 12(9):e0184575, 2017. e-Pub 2017. PMID: 28880939.
- Lin JS, Susztak K. Podocytes: the Weakest Link in Diabetic Kidney Disease?. Curr Diab Rep 16(5):45, 2016. PMID: 27053072.
- Khan R, Lin JS, Mata DA. Addressing Depression and Suicide Among Physician Trainees. JAMA Psychiatry 72(8):848, 2015. PMID: 26107398.
- Mata DA, Lin JS, Ramos MA. Can we predict future depression in residents before the start of clinical training?. Med Educ 49(7):741-2, 2015. PMID: 26077222.
- Lin J, Shi Y, Peng H, Shen X, Thomas S, Wang Y, Truong LD, Dryer SE, Hu Z, Xu J. Loss of PTEN promotes podocyte cytoskeletal rearrangement, aggravating diabetic nephropathy. J Pathol 236(1):30-40, 2015. e-Pub 2015. PMID: 25641678.
- Liu J, Johnson TV, Lin J, Ramirez SH, Bronich TK, Caplan S, Persidsky Y, Gendelman HE, Kipnis J. T cell independent mechanism for copolymer-1-induced neuroprotection. Eur J Immunol 37(11):3143-54, 2007. PMID: 17948266.
- Veeramani S, Igawa T, Yuan TC, Lin FF, Lee MS, Lin JS, Johansson SL, Lin MF. Expression of p66(Shc) protein correlates with proliferation of human prostate cancer cells. Oncogene 24(48):7203-12, 2005. PMID: 16170380.
- Morris RJ, Liu Y, Marles L, Yang Z, Trempus C, Li S, Lin JS, Sawicki JA, Cotsarelis G. Capturing and profiling adult hair follicle stem cells. Nat Biotechnol 22(4):411-7, 2004. e-Pub 2004. PMID: 15024388.
- Lee MS, Igawa T, Chen SJ, Van Bemmel D, Lin JS, Lin FF, Johansson SL, Christman JK, Lin MF. p66Shc protein is upregulated by steroid hormones in hormone-sensitive cancer cells and in primary prostate carcinomas. Int J Cancer 108(5):672-8, 2004. PMID: 14696093.
Abstracts
- Abudayyeh A, Suo L, Lin H, Mamlouk O, Yee C, Lin JS, Tchakarov A. A Pathological Immunological Approach in Evaluating ICI Induced Nephritis. American Society of Nephrology, 2022.
- Reddy V, Kala J, Msaouel P, Glass WF, Mamlouk O, Abudayyeh A, Lin JS. Treatment of PLA2R-Negative Membranous Nephropathy in the Setting of Immune Checkpoint Inhibitor and Renal Cell Carcinoma. American Society of Nephrology Annual Meeting, 2021.
- Lin JS, Tchakarov A, Abdel-Wahab n, Houssein S, Bentebibel S, Abdelrahim M, Yee C, Diab A, Abudayyeh A. Tertiary lymphoid structure gene signature detected in immune checkpoint inhibitor-associated renal immune related adverse event. Society of Immunotherapy for Cancer, 2021.
- Abudayyeh A, Suo L, Lin H, Mamlouk O, Yee C, Tcharkarov A, Lin JS. Predictors of ICI renal toxicity: a pathological approach. Society of Immunotherapy for Cancer, 2021.
- Lin JS, Green N, Long J, Chang B, Galvan D, Danesh FR. ARF6: a possible molecular target for Diabetic Kidney Disease?. American Society of Nephrology Annual Meeting, 2018.
- Lin JS, Lahoti A. Trifluridine and tipiracil-induced leukocytoclastic vasculitis with late-onset Henoch-Schönlein purpura nephritis. International Conference OncoNephrology, 2017.
- Lin JS, Mamlouk O, Glass WF, Amaria A, Lahoti A, Workeneh BT. Acute renal failure secondary to multifocal tubulointerstitial and intraglomerular metastatic malignant melanoma. International Conference OncoNephrology, 2017.
Book Chapters
- Mamlouk O, Lin, JS, Abudayyeh A. Nephrology (Kidney). In: Managing Immunotherapy Related Organ Toxicities. Springer. Springer, 2022.
Grant & Contract Support
| Date: | 2021 - 2022 |
| Title: | immune Checkpoint Urine Prognostic Profiling (i.C.U.P.P.) |
| Funding Source: | MD Anderson Cancer Center |
| Role: | Principal Investigator |
| Date: | 2020 - 2021 |
| Title: | Checkpoint Inhibitor Associated‐Nephritis: Identifying Predictors of Immunotoxicity |
| Funding Source: | MD Anderson Division of Internal Medicine Immuno-Oncology Toxicity Award Program |
| Role: | Principal Investigator |
| Date: | 2020 - 2021 |
| Title: | Research Bridge Funding |
| Funding Source: | MD Anderson Division of Internal Medicine |
| Role: | Principal Investigator |
| Date: | 2019 - 2024 |
| Title: | The role of ARF6 in the progression of diabetic kidney disease |
| Funding Source: | NIH/NIDDK |
| Role: | Principal Investigator |
| ID: | 1K08DK119466-01A1 |
| Date: | 2017 - 2019 |
| Title: | The functional role of ARF6-GEFs in nephrin-mediated podocyte cytoskeletal remodeling and endocytic nephrin trafficking |
| Funding Source: | American Society of Nephrology Ben J. Lipps Research Fellowship Program |
| Role: | Principal Investigator |
| Date: | 2016 - 2017 |
| Title: | The role of ARF6 in cytoskeletal dynamics in podocyte injury |
| Funding Source: | NIH/NIDDK |
| Role: | Principal Investigator |
| ID: | 1F32DK108566 |
Patient Reviews
CV information above last modified July 25, 2024